Axogen (AXGN) announced that the FDA has approved the biologics license application for Avance. Avance is an acellular nerve scaffold for the treatment of adult and pediatric patients aged one month or older with sensory, mixed, and motor peripheral nerve discontinuities.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN:
- AxoGen Secures FDA Approval for Avance Nerve Scaffold
- AxoGen initiated with an Outperform at Mizuho
- AxoGen price target raised to $26 from $25 at H.C. Wainwright
- AxoGen’s Strong Financial Performance and Strategic Advancements Justify Buy Rating
- AxoGen’s Strong Market Position and Growth Potential Justify Buy Rating